These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23019397)

  • 1. Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhage.
    Lee JG; Koh SJ; Yoo SY; Yu JR; Lee SA; Koh G; Lee D
    Korean J Intern Med; 2012 Sep; 27(3):317-26. PubMed ID: 23019397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher low-density lipoprotein cholesterol levels are associated with decreased mortality in patients with intracerebral hemorrhage.
    Chang JJ; Katsanos AH; Khorchid Y; Dillard K; Kerro A; Burgess LG; Goyal N; Alexandrov AW; Alexandrov AV; Tsivgoulis G
    Atherosclerosis; 2018 Feb; 269():14-20. PubMed ID: 29253643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicoradiological profile and serum lipid levels of intracerebral hemorrhage in prior statin users.
    Miura K; Yoshii Y; Nakamura Y; Ikeda K
    Intern Med; 2011; 50(13):1385-91. PubMed ID: 21720057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of LDL-cholesterol <1.8 mmol/L and statin use with the recurrence of intracerebral hemorrhage.
    Lee TC; Leung WC; Ho C; Chiu MW; Leung IY; Wong YK; Roxanna LK; Sum CH; Lui DT; Cheung RT; Leung GK; Chan KH; Teo KC; Lau KK
    Int J Stroke; 2024 Jul; 19(6):695-704. PubMed ID: 38429252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage.
    Mustanoja S; Strbian D; Putaala J; Meretoja A; Curtze S; Haapaniemi E; Sairanen T; Hietikko R; Sirén J; Kaste M; Tatlisumak T
    Stroke; 2013 Aug; 44(8):2330-2. PubMed ID: 23760210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
    Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K
    J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic loci for serum lipid fractions and intracerebral hemorrhage.
    Akoudad S; Ikram MA; Portegies ML; Adams HH; Bos D; Hofman A; Koudstaal PJ; Uitterlinden AG; van der Lugt A; van Duijn CM; Vernooij MW
    Atherosclerosis; 2016 Mar; 246():287-92. PubMed ID: 26820804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease.
    Yen CL; Fan PC; Lee CC; Chen JJ; Kuo G; Tu YR; Chu PH; Hsu HH; Tian YC; Chang CH
    J Am Heart Assoc; 2022 Oct; 11(19):e027516. PubMed ID: 36172933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage.
    Rodriguez-Luna D; Rubiera M; Ribo M; Coscojuela P; Pagola J; Piñeiro S; Ibarra B; Meler P; Maisterra O; Romero F; Alvarez-Sabin J; Molina CA
    Stroke; 2011 Sep; 42(9):2447-52. PubMed ID: 21799167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
    Jones PH; Nair R; Thakker KM
    J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation.
    Hajahmadi Pourrafsanjani M; Khayati Shal E; Khezrpour S
    High Blood Press Cardiovasc Prev; 2019 Feb; 26(1):37-43. PubMed ID: 30684247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: A prospective study.
    Ma C; Gurol ME; Huang Z; Lichtenstein AH; Wang X; Wang Y; Neumann S; Wu S; Gao X
    Neurology; 2019 Jul; 93(5):e445-e457. PubMed ID: 31266905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
    Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
    Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
    Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
    Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.